CONGRESS | POSTER | #SOHO2024 | Martin Hutchings Martin Hutchings presents extended follow-up from a pivotal phase II study of glofitamab monotherapy in pts with R/R #DLBCL (N=155) and subgroup analysis in pts with prior CAR-T cell therapy (N=52). Overall ORR was 52% with overall CR

CONGRESS | POSTER | #SOHO2024 | Yasmin Karimi Yasmin Karimi presents extended follow-up data beyond 2.5 years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at 30

CONGRESS | POSTER | #SOHO2024 | Ning Dong Ning Dong presents single center experience of SoC epcoritamab for R/R #LBCL (N=26). In this heavily pretreated population, the CR rate was 18.9% at median follow-up of 4 months, with PR in 31.8%. #lymphoma #lymsm #MedicalCongress

CONGRESS | POSTER | #SOHO2024 | Tamar Tadmor tamar tadmor presents the phase III BELLWAVE-011 study which will investigate nemtabrutinib vs ibrutinib or acalabrutinib in pts with treatment-naïve CLL/SLL (N=1,200). Primary objectives are to evaluate ORR and PFS, with secondary

📝 Phase III results from the TRANSFORM trial presented at #ASCO24 provide new insights for #LBCL; see: loom.ly/c0i9s_0 #lymphoma #lymsm #MedNews #MedEd manalikamdar

Paolo Ghia Università Vita-Salute San Raffaele shares the latest updates from the SEQUOIA trial of zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL. Watch the full video here: loom.ly/cPiqAoo #lymsm #lymphoma #EHA2024

CONGRESS | #SOHO24 | POSTER William Wierda Bill Wierda, MD, PhD MD Anderson Cancer Center presented 5.5 yr follow up of the phase II CAPTIVATE study. Fixed-duration ibrutinib+venetoclax treatment shows meaningful benefit in pts with CLL/SLL and high-risk genomic features (del(17p)/mutated TP53,

CONGRESS | #SOHO24 | POSTER Jan Burger MD Anderson Cancer Center reports 10-year analysis from RESONATE-2 study. 1L ibrutinib continues to show survival benefit in older adults with CLL/SLL including those with the high risk genomic clinical features. 9 yr PFS & OS were 49.7% & 68.0%; No

CONGRESS | #SOHO2024 William Wierda, MD Anderson Cancer Center, presents post hoc exploratory analysis results of the phase I/II TRANSCEND CLL 004 study evaluating characteristics associated with response to liso-cel in pts with R/R CLL/SLL (n=87). OR and CR rates did not correlate with

CONGRESS | #SOHO2024 William Wierda, MD Anderson Cancer Center, discusses whether continuous therapy is the best option for high-risk pts with CLL. In pts with del(17p)/TP53 mutations, second generation covalent BTK inhibitors (such as ibrutinib) show median PFS of 6+ years, however, are

A new study published in Blood Advances found that outpatient administration of commercially available CAR T-cell therapies, with no remote monitoring and early intervention for CRS, was safe and feasible 📝 More news: lymphomahub.com #lymphoma #MedNews #MedEd

CONGRESS | #SOHO2024 Gilles Salles Memorial Sloan Kettering Cancer Center discusses how to sequence therapies in R/R DLBCL, with the aim to optimize the chance of cure; concluding with a look to the future landscape and the possibility of achieving a cure amongst a substantial fraction of patients.

CONGRESS | #SOHO2024 Astrid Pavlovsky, Fundaleu, Buenos Aires, discusses accessing novel therapies for aggressive lymphoma; concluding that while there are significant advances in the management of lymphomas, there remains discrepancies in access to novel therapies and clinical

CONGRESS | #SOHO2024 Jason Westin Jason Westin, MD FACP MD Anderson Cancer Center shares data from the phase Ib trial of GOLCA+R-CHOP as 1L therapy in aggressive B-cell #lymphoma. ORR 0.2mg 82% and 0.4mg 88%, uMRD 0.2mg 73% and 0.4mg 90%, median DoR NR in either group, 12-mo PFS 0.4mg 85%, 120-mo

CONGRESS | #SOHO2024 Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL. Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose

3-year follow-up data from the phase III TRANSFORM trial presented at #ASCO24 show deep and durable responses with liso-cel vs SOC as second-line treatment for patients with R/R LBCL 📝 More news: lymphomahub.com #lymphoma #MedNews #MedEd manalikamdar

CONGRESS | #SOHO2024 Nina Wagner Johnston, Johns Hopkins Medicine, discusses the role of BTKi in frontline treatment of MCL. In older patients, addition of continuous ibrutinib to bendamustine and rituximab (BR) improved PFS however, worsened OS due to toxicity, while continuous

CONGRESS | #SOHO2024 Craig Portell, UVA Cancer Center, discusses sequencing therapies in R/R MCL. He advises considering prior exposure to BTKi when managing relapse in MCL. If the patient hasn't been previously exposed, a BTKi should be started. If they’re actively on a BTKi at

CONGRESS | #SOHO2024 Krish Patel, Providence Swedish, discusses novel investigational agents for the treatment of MCL, such as molecular glues/degraders, ADCs, novel CAR T cells, and BsAbs. Notable “off the shelf” therapies with meaningful activity include glofitimab monotherapy and